QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in
Related Questions
How might the strong Q2 results influence institutional and retail demand for DCTH stock in the short term?
What portion of total revenue is recurring versus one‑time sales, and what does that mean for future cash flow?
How does Delcath’s Q2 2025 growth compare with its direct competitors in the interventional oncology space?
How does the $22.5 million HEPZATO KIT™ revenue compare to consensus expectations and analyst forecasts?
Did the company provide guidance for Q3 or full‑year 2025, and how does that align with market expectations?
Are there any indications of product pipeline progress, regulatory milestones, or new indications that could further boost sales?
What is the gross margin on HEPZATO KIT™ sales and how might margin trends affect profitability going forward?
What is the status of the company’s cash position and burn rate given the rapid revenue expansion?
Are there any notable changes in the sales channel, pricing strategy, or reimbursement landscape that could impact future revenue?
What is driving the significant year‑over‑year revenue increase in Q2 2025 and is it sustainable?